ClinicalTrials.gg
Active, not recruitingNCT07221578Updated Aug 17, 2026

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

A Phase 3 interventional study of VQW-765 and Placebo in Social Anxiety Disorder (SAD), sponsored by Vanda Pharmaceuticals. Active, not recruiting at 30 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 187 studies in Phobia, Social with a site in United States — 23 open to participants now, 29 under way, 1 of them phase 3. Phobia, Social · United States.

Planned enrollment
6th of 178
500 · median 64
Started
2025
with 11 others
Phase 3
17 of 187
none open now
Primary completion
2026-12
later than 7 of 28 live
Registered
179th of 187
by date

Among the 187 studies in Phobia, Social with a site in United States, this one is the 6th largest by planned enrollment of the 178 interventional ones that give a count, is one of 12 that started in 2025, is one of 17 in phase 3, reaches primary completion later than 7 of the 28 other live ones, and was the 179th registered.

Phobia, Social

368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.

Browse Phobia, Social studies →

Open to participants now

23 of the 187 studies in Phobia, Social with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Phobia, Social with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

Read the detailed description

The study will enroll approximately 500 patients with current diagnosis of social anxiety disorder (SAD). Eligible participants will be randomly assigned to receive either a single oral dose of VQW-765 or placebo in a 1:1 ratio, followed by a psychosocial stress test. 1-2 weeks after the treatment visit, a safety follow-up assessment will be conducted remotely.

03

Conditions studied

  • Social Anxiety Disorder (SAD)

Browse trials for

Keywords

  • Social Anxiety Disorder
  • Social Phobia
  • SAD
  • Public Speaking Anxiety
  • Performance Anxiety
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability and willingness to provide written .
  2. Male and female subjects aged 18-65 years, inclusive.
  3. Current diagnosis of social anxiety disorder.
  4. Liebowitz Social Anxiety Scale total score ≥60.
  5. Public Speaking Anxiety Scale total score ≥60.
  6. Hamilton Depression Rating Scale score ≤18.

Exclusion criteria

Exclusion Criteria:

  1. Suicide attempts and/or suicidal ideation in the past 2 years or currently at risk of suicide in the opinion of the investigator.
  2. History of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders, obsessive-compulsive disorder, or autism spectrum disorder.
  3. Posttraumatic stress disorder or an eating disorder in the past 6 months.
  4. Substance or alcohol use disorder in the past 6 months or positive in drug/alcohol screening.
  5. Psychotherapy in the past 6 months.
  6. Psychotropic medication in the past 2 months.
  7. Current or planned pregnancy or nursing during the trial period.
  8. Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit of study participation, or interference with study objectives.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    VQW-765

    Drug: VQW-765

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugVQW-765

    oral capsule

  • DrugPlacebo

    oral capsule

06

What researchers measure

Primary outcomes

  1. Subjective Units of Distress Scale (SUDS)

    Subjective Units of Distress Scale (SUDS) during performance phase, scored from 0-100 with a higher score indicating higher distress.

    Time frame: 1 day

Secondary outcomes

  1. Subjective Units of Distress Scale (SUDS)

    Subjective Units of Distress Scale (SUDS) during anticipation phase, scored from 0-100 with a higher score indicating higher distress.

    Time frame: 1 day

  2. State-Trait Anxiety Inventory - State Anxiety Scale (STAI-S)

    State-Trait Anxiety Inventory - State Anxiety Scale (STAI-S), scored from 20 to 80 with higher scores indicating higher anxiety level.

    Time frame: 1 day

  3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Assessment of safety and tolerability of VQW-765, as measured by spontaneous reporting of adverse events (AEs)

    Time frame: 2 weeks

07

Study locations

30 sites
  • Vanda Investigational Site
    Phoenix, Arizona 85012, United States
  • Vanda Investigational Site
    Scottsdale, Arizona 85260, United States
  • Vanda Investigational Site
    Encino, California 91316, United States
  • Vanda Investigational Site
    Mission Viejo, California 92691, United States
  • Vanda Investigational Site
    San Diego, California 92123, United States
  • Vanda Investigational Site
    San Jose, California 95124, United States
  • Vanda Investigational Site
    Walnut Creek, California 94596, United States
  • Vanda Investigational Site
    Denver, Colorado 80209, United States
  • Vanda Investigational Site
    Jacksonville, Florida 32256, United States
  • Vanda Investigational Site
    Miami, Florida 33125, United States
  • Vanda Investigational Site
    Orlando, Florida 32801, United States
  • Vanda Investigational Site
    Tampa, Florida 33629, United States
  • Vanda Investigational Site
    Atlanta, Georgia 30329, United States
  • Vanda Investigational Site
    Suwanee, Georgia 30024, United States
  • Vanda Investigational Site
    New Orleans, Louisiana 70115, United States
  • Vanda Investigational Site
    Pikesville, Maryland 21208, United States
  • Vanda Investigational Site
    Rockville, Maryland 20852, United States
  • Vanda Investigational Site
    Towson, Maryland 21204, United States
  • Vanda Investigational Site
    Saint Charles, Missouri 63304, United States
  • Vanda Investigational Site
    St Louis, Missouri 63182, United States
  • Vanda Investigational Site
    Las Vegas, Nevada 89102, United States
  • Vanda Investigational Site
    Princeton, New Jersey 08540, United States
  • Vanda Investigational Site
    Albuquerque, New Mexico 87109, United States
  • Vanda Investigational Site
    New York, New York 10016, United States
  • Vanda Investigational Site
    New York, New York 10036, United States
  • Vanda Investigational Site
    Charlotte, North Carolina 28210, United States
  • Vanda Investigational Site
    Wilmington, North Carolina 28403, United States
  • Vanda Investigational Site
    Houston, Texas 77081, United States
  • Vanda Investigational Site
    Wichita Falls, Texas 76309, United States
  • Vanda Investigational Site
    Orem, Utah 84097, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2025
First posted
Oct 28, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07221578
Responsible party
Sponsor
First posted
Oct 28, 2025
Start date
Sep 22, 2025
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Aug 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion